U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.2296T>A (p.Tyr766Asn) AND Glycogen storage disease, type II

Germline classification:
Pathogenic/Likely pathogenic (2 submissions)
Last evaluated:
Sep 23, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001302690.6

Allele description [Variation Report for NM_000152.5(GAA):c.2296T>A (p.Tyr766Asn)]

NM_000152.5(GAA):c.2296T>A (p.Tyr766Asn)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.2296T>A (p.Tyr766Asn)
HGVS:
  • NC_000017.11:g.80117074T>A
  • NG_009822.1:g.20519T>A
  • NM_000152.5:c.2296T>AMANE SELECT
  • NM_001079803.3:c.2296T>A
  • NM_001079804.3:c.2296T>A
  • NP_000143.2:p.Tyr766Asn
  • NP_001073271.1:p.Tyr766Asn
  • NP_001073272.1:p.Tyr766Asn
  • LRG_673:g.20519T>A
  • NC_000017.10:g.78090873T>A
  • NM_000152.3:c.2296T>A
Protein change:
Y766N
Links:
dbSNP: rs941181575
NCBI 1000 Genomes Browser:
rs941181575
Molecular consequence:
  • NM_000152.5:c.2296T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079803.3:c.2296T>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079804.3:c.2296T>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Glycogen storage disease, type II (GSD2)
Synonyms:
ACID ALPHA-GLUCOSIDASE DEFICIENCY; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM; GSD II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009290; MedGen: C0017921; Orphanet: 365; OMIM: 232300

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001491908Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely pathogenic
(Sep 23, 2023)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

SCV002780902Fulgent Genetics, Fulgent Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Mar 23, 2022)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.

Kishnani PS, Gibson JB, Gambello MJ, Hillman R, Stockton DW, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Day JW, Wang RY, Goldstein JL, An Haack K, Sparks SE, Zhao Y, Hahn SH; Pompe ADVANCE Study Consortium..

Genet Med. 2019 Nov;21(11):2543-2551. doi: 10.1038/s41436-019-0527-9. Epub 2019 May 14.

PubMed [citation]
PMID:
31086307
PMCID:
PMC8076035

Quantitative computed tomography for enzyme replacement therapy in Pompe disease.

Yonee C, Toyoshima M, Young SP, Maruyama S, Higuchi I, Narita A, Maegaki Y, Nanba E, Ohno K, Kawano Y.

Brain Dev. 2012 Nov;34(10):834-9. doi: 10.1016/j.braindev.2012.01.013. Epub 2012 Apr 21.

PubMed [citation]
PMID:
22521436
See all PubMed Citations (6)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001491908.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 766 of the GAA protein (p.Tyr766Asn). This variant is present in population databases (no rsID available, gnomAD 0.002%). This missense change has been observed on the same chromosome as p.Pro522Ser in individual(s) with Pompe disease (PMID: 31086307). ClinVar contains an entry for this variant (Variation ID: 1005758). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function. This variant disrupts the p.Tyr766 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22521436, 22538254, 28394184). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Fulgent Genetics, Fulgent Genetics, SCV002780902.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024